Our Logo

Our Team

 

UPDATED on 7/23/2019

Founder’s Vision

Dr. Aviva Lev-Ari, PhD, RN is an alumna of University of California, Berkeley, PhD’83. Dr. Lev-Ari was nominated for the 2019 Alumni of the Year Award followed by 2020 Campanile Excellence in Achievement Awards nomination forthcoming, 11/2019. August 2018-July 2021, Dr. Lev-Ari serves the Massachusetts Academies of Sciences (MAS) as Liaison to the Biotechnology and eScientific Publishing industries. She serves as Board member, Fellow, and Advisor to the Governing Board http://www.maacadsci.org.

LPBI Group as a venture was launched in 4/2012 by Dr. Lev-Ari and she is leading it since its inception. These significant accomplishments were achieved in

• Pharmaceutical (Biomed e-Series, 16 volumes in the frontiers of Life Sciences and Medicine, average volume size: 2,400 pages, 96,000 page downloads),
• Media (e-Proceedings of Biotech Conferences, 70 events covered, 2013 to Present) and
• electronic Scientific Publishing (Open Access Online Scientific Journal, 1.7 Million readers, ~5,700 articles)

The growth in all the three domains, above, took place during that period and led to her nomination for the 2018 Yidan Prize.

[Nomination for 2018 Yidan Prize, recognition in the field of MEDICAL education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/10/21/nomination-for-2018-yidan-prize-recognition-in-the-field-of-medical-education-development-of-curation-methodologies-for-scientific-content-2018-nominee-aviva-lev-ari-phd-rn/]

Dr. Aviva Lev-Ari is the Director and Founder of a pharmaceutical media and digital scientific publishing group called Leaders in Pharmaceutical Business Intelligence (LPBI) Group, which owns the intellectual property in three interrelated healthcare content products:

1. IP Asset Class I.An on-line open access pharma scientific journal which has published about 5700 articles which have been read by over 1 1/2 million readers (1,640,034 as of 7/1/2019). http://pharmaceuticalintelligence.com 
2. IP Asset Class II.A series of 16 e-books in five medical specialities, including cardiovascular, genomics, cancer, immunology and precision medicine – these are available on Amazon https://lnkd.in/ekWGNqA
3. IP Asset Class III. An electronic corpus of the proceedings of 70 top Global Biomed scientific and Medical conferences. https://pharmaceuticalintelligence.com/press-coverage/

These three IP Asset Classes represent a vast IP portfolio owned by LPBI Group.

We are currently exploring in North America, Europe and Southeast Asia, prospective acquisition opportunities for these IP resources [vast content, digital printed products, platform, methods, methodologies and systems]. A prospective acquirer would be an establishment, a corporation or an institute that will be able to carry these IP resources forward under new ownership and new management, as a new company. Following the knowledge transfer phase, the current team can continue pursuing their expertise under the new ownership and the new management. This is a concept of an M&A. Alternatively, a sale outright of the portfolio of IP could be considered under certain terms and conditions.

It is Dr. Aviva Lev-Ari’s belief that this newly to be established organizational entity would provide employment to dozens of Postdocs in the Life Sciences, who face a small number of Academic openings in the LIfe Sciences in the developed countries. It will attract Medical Doctors interested in writing clinical interpretations to basic life sciences primary research outcomes using the methodology of curation for scientific findings developed by Dr. Lev-Ari and her Team as demonstrated in the 5,700 articles in the Journal mentioned above which to date had attracted ~8000 comments by Scientist eReaders around the Globe using in search the +10,000 tags and the 670 categories of research which form the Ontology of the Journal.

Following such a transaction, these three vast IP assets will be hosted on a Cloud Web Services platform architecture managed by the new ownership and offering to the Public the advantages of global accessibility [under terms and conditions].

These resources could be accessed on a National level (Country x,y,z) or at the EU level or another geography by

1. All Life Science Incubators
2. All Biotech Start ups
3. All Life Sciences Departments in any Higher EducationInstitute
4. All Medical Schools: Faculties using the content for curriculum development, Research Staff and Medical Students
5. All High school students writing Honor Final thesis in Life Sciences
6. All private individuals seeking knowledge in the Life Sciences & Medicine, Pharmaceutics and Health Care
7. Private & Public interests can be served: the Biotech/Healthcare sectors, Education Sectors, and
8. it can in parallel have a few business lines that are fully commercial for parties beyond Country x,y,z or the EU or another geography, i.e., Global and International NGOs such as Teva, IBM, GE Health, Siemens Healthineers, National’s HMOs can use the platform for Medical Doctors and Allied Health professionals continuing education using the contents of each of the three IP asset classes.

Human Capital and the Content Creation Process

• The two Board Members, Dr. Stephen J. Williams and Dr. Marcus W. Feldman are fully involved in venture’s decision making activities.
• The LPBI Group’s team members are all Experts, Authors, experienced Writers professing the Curation methodology applied for content creation in Translational Medicine from Life Sciences to bedside Medicine, Genomics, Bioinformatics, AI in Radiology and Pathology and Precision Medicine, Cancer, Cardiovascular diseases and Cardiac Imaging, Immunology, Infectious diseases, BioMedicine, Biotechnology, Pharmaco-therapy, Medical Technology and Health Care.

In House Business and Management Tool Development

• The LPBI Group’s Business Team had developed an extensive business plan for the potential acquirers of these three IP asset classes. Twelve industries were identified. The Business Plan and the Opportunities Map are ready for perusal.

https://pharmaceuticalintelligence.com/2019-vista/

• Full documentation of Intangible and of Tangible assets is updated quarterly.

2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis 

• The team developed a calculator for valuation of LPBI Group’s IP by contributing factors to value creation [in beta phase: IP-VAL-CALC]
• The Opportunities Map, the Business plan and a detailed document describing the technology and the pipeline of new products and Content as a Service (CAAS), all three can be used for design of new PowerPoint Presentations in different languages customized to each acquirer’s identified industry, within each of the 12 industries. A Presentation per industry, presented to several potential acquirers within each industry.

Dr. Lev-Ari is bringing to the table a business candidate for an acquisition of the Intellectual property vast portfolio – three asset classes for common access by the entire BIOTECH Industry in Country x,y,z or the EU or another geography. The leading Global Conference Organizers for Global audiences in Biotech would benefit from IP Class III, and make it a product they currently do not have.

Dr. Lev-Ari is interested in finding half a dozen appropriate potential acquirers, preferably in several geographies, who would champion the technology, the infrastructure, and the contents in Health care to continue this amazing series of accomplishments in three Industries:

1. Pharmaceutical (BioMed eBooks),
2. Media (e-Proceedings) and
3. electronic Scientific Publishing (Journal).

UPDATED on 2/10/2019

Leaders in Pharmaceutical Business Intelligence (LPBI) Group is an electronic scientific publishing venture that has developed platform architecture methodologies and business models of intellectual property development via scientific content creation by curation. These aspects of our intellectual property assist the e-Scientific Publishing Industry and scientific information users to mitigate the information explosion of scientific articles in the Life Sciences and Medicine and their inevitable immediate obsolescence.

The work produced by LPBI Group is a team effort within the key domains of BioMed, BioTech, Pharmaco-therapy, MedTech, Health Care and the Life Sciences-Medicine connection. Our system technologies, which include platforms, methodologies and models, also include development of significant content materials. Additionally, this work can be replicated in many fields, i.e., Legal, Economics, Finance, International Relations, as examples of disciplines. It should be noted that all of LPBI’s material could, in principle, be translated into other languages.

All members of our team have at least 10 years of experience in the life sciences area and have been trained to master the methodology of scientific curation used in our articles, in turn, if selected by experienced editors, these articles are targeted for inclusion in our books. The members of the team include senior MDs, MD/PhDs, FACC, FCAP, PharmDs and senior PhDs who expressed interest in medical writing and clinical interpretation of basic research, translational research and interpretation of clinical trials outcomes.

Highly qualified content consultants are involved in each of the five e-series (senior MDs, MD/PhDs, and Professors) are engaged in the production of our curations. The topics for article curations and for the contents of the books we have created are carefully edited; I am the editor-in-chief and lead this multidisciplinary content compilation using my diverse areas of technical training and experience.

Our intellectual property “IP” consists of three classes of assets as described in detail within live links in the below, listed article.

• First, the Journal, an ongoing journal of curated, current biomedical research;
• Second, the books, a collection of 16 volumes of e-books available via Amazon in five specialties of Medicine: Cardiovascular, Genomics, Cancer, Immunology and Precision Medicine; and
• Third, real-time curation of biotech and medical conferences yielding an e-Proceedings at the end of the conference in One-click operation.

These three IP asset classes are described in details with live links in

eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model

https://pharmaceuticalintelligence.com/2019/02/04/escientific-publishing-a-case-in-point-evolution-of-platform-architecture-methodologies-and-of-intellectual-property-development-content-creation-by-curation-business-model/

LPBI’s business is scalable, and the skill set needed for curation of scientific findings for clinical interpretations, as well as in other disciplines can be augmented by appropriate training in the curation methodology to be offered to experts in many fields. We have shown that synergy among experts, authors and writers yields outstanding collaborations in producing our curations. There are many post-doctoral individuals in biotech industries and academia who can serve as experts, authors and writers in continuing LPBI’s operations, following appropriate onboarding.

The link, above is a summary of six demonstrations that justify these claims. The list of six points is followed by an extensive description of these valuable attributes of LPBI IP. The table for POINT #4 presents a concise summary of the functions and forms of LPBI IP three asset classes.

 

UPDATED on 12/4/2018

 

UPDATED on 4/2/2018

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

https://pharmaceuticalintelligence.com/2017/06/20/e-scientific-publishing-the-competitive-advantage-of-a-powerhouse-for-curation-of-scientific-findings-and-methodology-development-for-e-scientific-publishing-lpbi-group-a-case-in-point/

 

Material below that point is OUTDATED 

This section is under construction

MultiMedia Presence

• Twitter.com: http://twitter.com/pharma_BI

@pharma_BI

• FaceBook Page

http://www.facebook.com/LeadersInPharmaceuticalBusinessIntelligence

• Launchers of a Professional Group on LinkedIn

http://www.linkedin.com/groups?gid=4346921&trk=hb_side_g

• Company Page on LinkedIn

https://www.linkedin.com/company/9325543?trk=vsrp_companies_res_name&trkInfo=VSRPsearchId%3A875971435604472931%2CVSRPtargetId%3A9325543%2CVSRPcmpt%3Aprimary

e-Book Titles by LPBI

For more information on Real-Time Conference Coverage and a full listing of Conferences Covered by LPBI please go to:

https://pharmaceuticalintelligence.com/press-coverage/

Leaders in Pharmaceutical Business Intelligence is a Holding Company of Six Ventures:

Venture Overview Updated in New Company Page on LinkedIn: Leaders in Pharmaceutical Business Intelligence – 3/7/2015

https://pharmaceuticalintelligence.com/2015/03/07/venture-overview-updated-on-new-company-page-on-linkedin-leaders-in-pharmaceutical-business-intelligence/

• VENTURE #1:

e-Publishing: Medicine, HealthCare, Life Sciences, BioMed, Pharmaceutical– Open Access Online Scientific Journal

http://pharmaceuticalintelligence.com

• VENTURE #2:

BioMedical e-Books e-Series: Cardiovascular, Genomics, Cancer, BioMed, Patient Centered Medicine

https://pharmaceuticalintelligence.com/biomed-e-books/

2013 e-Book on Amazon.com

Perspectives on Nitric Oxide in Disease Mechanisms, on Amazon since 6/2/12013

http://www.amazon.com/dp/B00DINFFYC

2015 e-Book on Amazon.com

1. Metabolic Genomics and Pharmaceutics, on Amazon since 7/21/2015

http://www.amazon.com/dp/B012BB0ZF0

2. Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

3. Genomics Volume One

4. Physiology, Genomics and Pharmaceutical

5. Cardiovascular, Volume Two: Co-Curation, Methodology

6. Cardiovascular Diseases, Volume Three: Etiology, Genetics and Genomics

7. Cardiovascular Diseases, Volume Four: Regenerative and Translational Medicine

8. Cancer Volume Two: Immunotherapy, Nanotechnology in drug delivery

2016 we need to FIND Editors for Two e-Books

– Genomics Volume Two on NGS – Dr. Williams and another Editor

– Patient Voice on Invasive Procedures – New Editor

2016, We will continue with

– Aviva will work with Larry on CVD 5: Pharmacology-Therapy, 

– With Adam and Dr. Pearlman, on CVD 6: Cardiac Surgery and Interventional

– With Adam and Dr. Pearlman, on CVD 7: CV Imaging

– Dr. Pearlman alone: 

Three CVD Hardcopy Volumes, 1-Etiology, 2-Diagnostics, 3-Therapies

• VENTURE #3:

International Scientific Delegations https://pharmaceuticalintelligence.com/scientific-delegation

• VENTURE #4:

Funding, Deals & Partnerships

https://pharmaceuticalintelligence.com/joint-ventures/

Business Development Plan for LPBI

– investors in Shanghai, China for funding Biologics and Medical Devices (Wilferd van Opstal)

– investors in Switzerland to find an e-Publisher to buy the Journal and the e-Books (Gerard Loiseau)

– a 3D Printing Swiss company – RegenHU — to establish Partnerships with MIT, GE, J&J [Adam on P&G]

– Adam drafts Patents with Bill Zurn on implantable Cardiovascular device – I am discussing Zurn’s IP with investors in Shanghai and NYC

– I work with investors in NYC (Nicholas Hall, Private Wealth Management, Maxim Group LLC) on Deals, Funding and Partnerships

• VENTURE #5:

IP Invented HERE!

• VENTURE # 6:

Real Time PRESS Coverage International Biotech Conferences

https://pharmaceuticalintelligence.com/press-coverage/

Our Growth Needs: Leaders in Pharmaceutical Business Intelligence

 

 Our Business Portfolio

VENTURE #1:

e-Publishing: Medicine, HealthCare, Life Sciences, BioMed, Pharmaceutical

• Open Access Online Scientific Journal

11/19/2014 – PRESS RELEASE — Over 500,000 Unique Site Visits reached by PharmaceuticalIntelligence.com Reported today by Leaders in Pharmaceutical Business Intelligence (LPBI)

https://pharmaceuticalintelligence.com/2014/11/19/over-500000-unique-site-visits-reached-by-pharmaceuticalintelligence-con-reported-today-by-leaders-in-pharmaceutical-business-intelligence-lbpi/

http://pharmaceuticalintelligence.com

• Scoop.it!.com

1. http://www.scoop.it/t/cardiotoxicity
2. http://www.scoop.it/t/cardiovascular-and-vascular-imaging
3. http://www.scoop.it/t/cardiovascular-disease-pharmaco-therapy

VENTURE #2:

1. BioMedical e-Books e-Series: Cardiovascular, Genomics, Cancer, BioMed, Patient Centered Medicine

https://pharmaceuticalintelligence.com/biomed-e-books/

• Series A: e-Books on Cardiovascular Diseases
• Series B: Frontiers in Genomics Research
• Series C: e-Books on Cancer & Oncology
• Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases
• Series E: Titles in the Strategic Plan for 2014-2015

2. on Amazon’s Kindle e-Books List since 6/2013

• Perspectives on Nitric Oxide in Disease Mechanisms

3. Plans for Volume 1,2,3 – Hardcover

• Cardiovascular Diseases: Causes, Risks and Management – Volume 1,2,3 – Hardcover

4. Schedule Plan for e-Publishing on Amazon.com

• Publishing on Amazon Kindle – SIX Volumes in 2015:

1.  Metabolomics, Volume One

2.  Genomics, Volume One

3.  Cancer Volume One

4.  Cardiovascular – Volume 2

5.  Cardiovascular – Volume 3

6.  Cardiovascular – Volume 4

• Publishing on Amazon Kindle – Four Volumes in 2016:

1.  Physiology, PharmacoTherapy and Genomics: The Patient-centered Medicine Perspective

2.  Cancer, Volume Two

3.  Cardiovascular – Volume 5

4.  Cardiovascular – Volume 6

VENTURE #3:

International Scientific Delegations https://pharmaceuticalintelligence.com/scientific-delegation/

• Shanghai, May 2015
• Barcelona, Spain, November 2015
• Amsterdam, May 2016
• Geneva, November 2016

VENTURE #4: 

Funding, Deals & Partnerships

https://pharmaceuticalintelligence.com/joint-ventures/

• Corporate Clients for our Services
• Funding Cardiovascular Medical Devices Development
• Funding Biologics Development
• Funding Diagnostics
• Funding Partnerships in IP Development
• M&A and Exit
• Targeting Penetration in New Markets for High Technology Products
• Management of Engineering Design of Prototypes Outsourcing

VENTURE #5:

IP Invented HERE!

1.  Development of a NEW Nitric Oxide monitor to Alpha Szenszor Inc. sensor portfolio. A concept for a low cost POC e-nose, capable of real time ppb detection of Cancer The Cancer Team at Leaders in Pharmaceutical Business Intelligence under the leadership of Dr. Williams 2.  Development of a NEW Nitric Oxide monitor to Alpha Szenszor Inc. sensor portfolio. A concept for Inhaled Nitric Oxide for the Adult HomeCare Market – IP by Dr. Pearlman and Dr. A. Lev-Ari

a.  iknow iNO is i-kNOw – Inhaled Nitric Oxide for the HomeCare Market https://pharmaceuticalintelligence.com/2013/10/16/iknow-ino-is-i-know-inhaled-nitric-oxide-for-the-homecare-market/

b. electronic Book on Nitric Oxide by Nitric Oxide Team @ Leaders in Pharmaceutical Business Intelligence (LPBI)

Perspectives on Nitric Oxide in Disease Mechanisms

http://www.amazon.com/dp/B00DINFFYC

c. The rationale and use of inhaled NO in Pulmonary Artery Hypertension and Right Sided Heart Failure Larry H. Bernstein 8/20/2012

d. Inhaled Nitric Oxide in Adults: Clinical Trials and Meta Analysis Studies – Recent Findings

Aviva Lev-Ari, PhD, RN, 6/2/2013

e. Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care

Aviva Lev-Ari, PhD, RN, 6/3/2013

3.  Cancer Genomics for NEW product development in diagnosis and treatment of Cancer Patients using sensory technology with applications for Radiation Therapy – The Cancer Team at Leaders in Pharmaceutical Business Intelligence under leadership of Dr. Larry H Bernstein, MD, FCAP

4.  Developing Mitral Valve Disease: MRI Methods and Devices for Percutaneous Mitral Valve Replacement and Mitral Valve Repair Augmentation of Patented Technology using RF – Dr. Pearlman’s IP Non-Hardware Mitral Annuloplasty – Dr. Justin D. Pearlman

https://pharmaceuticalintelligence.com/joint-ventures/valvecure-llc/non-hardware-mitral-annuloplasty-dr-justin-d-pearlman/

5.  Novel Technology using MRI for Vascular Lesions, Tumors, Hyperactive Glands and non-Surgical Cosmetic Reconstruction – Dr. Pearlman’s IP

http://pharmaceuticalintelligence.com/biomed-e-books/series-a-e-books-on-cardiovascular-diseases/httppharmaceuticalintelligence-combiomed-e-bookscardiovascular-diseases-causes-risks-and-management/cvd-business-affairs/mitral-valve-disease-mri-methods-and-devices/

VENTURE # 6:

PRESS Coverage of Conferences

https://pharmaceuticalintelligence.com/press-coverage/

This page has the following sub pages.

• 2019 Strategic Marketing of LPBI Group’s Intellectual Property: Strength & Markets